| 51 |
30234108 | Aberrations of DNA Repair Pathways in Prostate Cancer: Future Implications for Clinical Practice? | 2018 |
1 |
| 52 |
31501807 | Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations. | 2018 |
1 |
| 53 |
32913984 | Polyclonal BRCA2 Reversion Mutations Detected in Circulating Tumor DNA After Platinum Chemotherapy in a Patient With Metastatic Prostate Cancer. | 2018 |
1 |
| 54 |
27739325 | A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. | 2017 Feb |
1 |
| 55 |
27908594 | Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. | 2017 Jan |
1 |
| 56 |
28087643 | Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance. | 2017 Jul 1 |
3 |
| 57 |
28291774 | BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. | 2017 Apr 11 |
2 |
| 58 |
28467918 | Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial. | 2017 Aug |
1 |
| 59 |
28588062 | Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. | 2017 Sep |
3 |
| 60 |
28604461 | Chemosensitivity of BRCA1-Mutated Ovarian Cancer Cells and Established Cytotoxic Agents. | 2017 Oct |
1 |
| 61 |
28608931 | The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. | 2017 Sep 15 |
3 |
| 62 |
28623073 | Commentary on "Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer". Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B. Eur Urol. Jun 2016;69(6):992-5. | 2017 Aug |
2 |
| 63 |
28626402 | Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer. | 2017 May-Aug |
2 |
| 64 |
28765325 | Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. | 2017 Nov 1 |
2 |
| 65 |
26724258 | Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer. | 2016 Jun |
2 |
| 66 |
26785283 | Ovarian cancer treatment in mutation carriers/BRCAness. | 2016 Oct |
1 |
| 67 |
26964893 | Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response. | 2016 May |
1 |
| 68 |
27511924 | Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers. | 2016 Oct |
2 |
| 69 |
28003870 | New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes. | 2016 Sep |
2 |
| 70 |
25537514 | The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2. | 2015 Feb 10 |
1 |
| 71 |
25993149 | Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different? | 2015 |
1 |
| 72 |
26015868 | Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. | 2015 |
2 |
| 73 |
26210103 | Molecular landscape of prostate cancer: implications for current clinical trials. | 2015 Nov |
1 |
| 74 |
24624361 | Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System. | 2014 |
2 |
| 75 |
25076338 | PARP-inhibitors in BRCA-associated pancreatic cancer. | 2014 Jul 28 |
1 |
| 76 |
25093514 | Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. | 2014 Jun 3 |
1 |
| 77 |
25186150 | Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation. | 2014 Oct |
1 |
| 78 |
23265709 | Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer. | 2013 Apr |
2 |
| 79 |
23964347 | Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study. | 2013 |
1 |
| 80 |
21756279 | Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer. | 2012 Mar |
1 |
| 81 |
22176776 | Will Chinese ovarian cancer patients benefit from knowing the BRCA2 mutation status? | 2012 Jan |
1 |
| 82 |
21378390 | Melphalan as a treatment for BRCA-related ovarian carcinoma: can you teach an old drug new tricks? | 2011 Oct |
1 |
| 83 |
21709188 | Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. | 2011 Aug 1 |
1 |
| 84 |
21819606 | Drug therapy for hereditary cancers. | 2011 Aug 6 |
1 |
| 85 |
21990299 | Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. | 2011 Oct 12 |
2 |
| 86 |
19574032 | Dramatic response to platinum in a patient with cancer with a germline BRCA2 mutation. | 2009 Aug |
2 |
| 87 |
19602291 | Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. | 2009 Jul 14 |
3 |
| 88 |
18264087 | Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. | 2008 Feb 28 |
2 |
| 89 |
18413725 | Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. | 2008 Apr 15 |
1 |
| 90 |
18720553 | Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance. | 2008 Jul |
3 |
| 91 |
17855454 | Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. | 2007 Oct 1 |
1 |